Search clinical trials for: Catumaxomab

Total 21 results

Neovii Biotech
Fresenius Biotech North America

Completed

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Malignant Ascites

United States
Neovii Biotech

Completed

Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites (SECIMAS)

Malignant Ascites Due to Epithelial Carcinoma

Germany
Neovii Biotech

Completed

Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma

Gastric Cancer | Gastric Adenocarcinoma

Germany
Neovii Biotech
Fresenius Biotech North America

Completed

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Ovarian Cancer

United States
Gustave Roussy, Cancer Campus, Grand Paris

Terminated

Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab (IIPOP)

Patients With Gastric Peritoneal Carcinomatosis

France
Neovii Biotech

Completed

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

Malignant Ascites | EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)
Neovii Biotech

Terminated

A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients

Epithelial Cancer Patients

Austria, Denmark, Spain
LintonPharm Co.,Ltd.

Recruiting

Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine

Bladder Cancer

China
Neovii Biotech

Completed

Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection

Gastric Cancer | Gastric Adenocarcinoma

Austria, Spain, United Kingdom, Germany
Lindis Biotech GmbH

Recruiting

Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

Urinary Bladder Neoplasms

Germany
Grupo Español de Investigación en Cáncer de Ovario
Neovii Biotech

Completed

Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission

Ovarian Cancer

Spain
Neovii Biotech

Completed

Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

Ovarian Cancer | Epithelial Ovarian Cancer

Austria, Germany
Neovii Biotech

Terminated

Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer (IV REXBC 02)

Breast Cancer | Breast Neoplasms

Belgium
JSehouli

Completed

Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer

Recurrent Epithelial Ovarian Cancer

Germany
Neovii Biotech

Terminated

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment

Advanced Breast Cancer | Metastatic Breast Cancer

Spain, Austria, France, Germany, Italy
Krankenhaus Nordwest

Terminated

Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors

Her2/Neu Positive Advanced Solid Tumors

Germany
Neovii Biotech
Fresenius Biotech North America

Terminated

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

Advanced Breast Cancer | Metastatic Breast Cancer

United States, Canada
AIO-Studien-gGmbH
Neovii Biotech

Completed

Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas (CatuNeo)

Gastric Adenocarcinoma With Peritoneal Carcinomatosis | Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis | Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis

Germany
LintonPharm Co.,Ltd.

Recruiting

Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis

Stomach Neoplasms

China, Korea, Republic of, Taiwan
AGO Study Group

Completed

Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Cancer

Germany
Neovii Biotech

Completed

CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers (CASIMAS)

Neoplasms | Carcinoma | Cancer | Malignant Ascites

France, Germany, Italy, Spain

3

Subscribe